Celltrion Inc
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- -
- Established
- 1999-01-01
- Employees
- -
- Market Cap
- $31.9B
- Website
- http://www.celltrion.com/
A Bioequivalence Study of L04TD2 Compared to Administration of L04RD1 in Healthy Volunteers
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 50
- Registration Number
- NCT05581693
- Locations
- 🇰🇷
Jaewoo Kim, Seoul, Korea, Republic of
A Bioequivalence Study of L04TD1 Compared to Administration of L04RD1 in Healthy Volunteers
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 50
- Registration Number
- NCT05568121
- Locations
- 🇰🇷
H plus Yangji Hospital, Seoul, Korea, Republic of
To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 367
- Registration Number
- NCT05495568
- Locations
- 🇪🇪
CT-P17 3.3 investigational site, Tallinn, Estonia
A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 471
- Registration Number
- NCT05489224
- Locations
- 🇵🇱
INTER CLINIC Piotr Adrian Klimiuk, Bialystok, Poland
Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 890
- Registration Number
- NCT05385770
- Locations
- 🇰🇷
Celltrion, Incheon, Korea, Republic of
A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 48
- Registration Number
- NCT05363592
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Korea, Republic of
A Food Effect Study of CT-L01 After Oral Administration in Healthy Volunteers
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 24
- Registration Number
- NCT05364164
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Korea, Republic of
A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 48
- Registration Number
- NCT05363384
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Korea, Republic of
To Evaluate the Safety and Efficacy of Inhaled CT-P63 and CT-P66 Combination Therapy in Symptomatic Patients With COVID-19 Not Requiring Supplemental Oxygen
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Celltrion
- Registration Number
- NCT05224856
A Study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 300
- Registration Number
- NCT05188378
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
© Copyright 2024. All Rights Reserved by MedPath